Skip to content

US · ISPC · MEDICAL - DIAGNOSTICS & RESEARCH

iSpecimen Inc. (ISPC) intrinsic value and stock valuation

$0.46as of 2026-11-21 · Mkt cap 266.62K

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

iSpecimen Inc. DCF and intrinsic value

InvestorsCraft values ISPC with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ISPC’s statements →

iSpecimen Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Diagnostics & Research Woburn, MA 01801 ispecimen.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$1.93M-25.1% 5y CAGRd
20182025
Net income
-$-10.49M
20182025
Free cash flow
-$-4.24M
20182025
Total equity
$3.09M
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$1.93M$9.29M$9.93M$10.4M$11.1M
Operating income-$-8.98M-$-12.73M-$-11.17M-$-10.19M-$-5.93M
Net income-$-10.49M-$-12.5M-$-11.1M-$-10.25M-$-8.96M
EPSd-$-87.42M-$-625M-$-1.11B-$-1.03B-$-896M
Operating cash flow-$-4.24M-$-8.26M-$-5.81M-$-5.82M-$-10.67M
Capital expenditure-$0.00-$-60K-$-4.74M-$-3.19M-$-1.04M
Free cash flow-$-4.24M-$-8.3M-$-10.55M-$-9.01M-$-11.71M
Total assets$9.53M$9.35M$15.8M$24.6M$35.7M
Total debt$270K$310K$200K$190K$3.42M
Net debt-$-6.61M-$-1.57M-$-2.15M-$-15.12M-$-24.32M
Total equity$3.09M$3.31M$9.74M$20.3M$29.8M
Cash and short-term investments$6.88M$1.88M$5.01M$15.3M$27.7M
Income statement
20252024202320222021
Revenue$1.93M$9.29M$9.93M$10.4M$11.1M
Cost of revenue$1.9M$5.3M$4.82M$4.76M$5.25M
Gross profit$20K$3.99M$5.11M$5.65M$5.89M
Research and development expenses$2.16M$3.53M$3.57M$2.66M$1.84M
Selling, general and administrative expenses$6.6M$12.7M$11.7M$12.4M$9.4M
Other expenses$250K$540K$1.03M$800K$570K
Operating expenses$9M$16.7M$16.3M$15.8M$11.8M
Cost and expenses$10.9M$22M$21.1M$20.6M$17.1M
Interest income$0.00$40K$340K$170K$10K
Interest expense$0.00$220K$230K$240K$2.1M
Depreciation and amortization$1.73M$2.29M$2.07M$1.21M$1M
Ebitda-$-8.75M-$-10.38M-$-8.8M-$-8.8M-$-5.86M
Operating income-$-8.98M-$-12.73M-$-11.17M-$-10.19M-$-5.93M
Total other income/expenses, net-$-1.51M$230K$70K-$-60K-$-3.04M
Income before tax-$-10.49M-$-12.5M-$-11.1M-$-10.25M-$-8.96M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-10.49M-$-12.5M-$-11.1M-$-10.25M-$-8.96M
Weighted average shares outstanding$120K$20K$10K$10K$10K
Weighted average diluted shares outstanding$120K$20K$10K$10K$10K
Balance sheet
20252024202320222021
Cash and short-term investments$6.88M$1.88M$5.01M$15.3M$27.7M
Net receivables$50K$1.44M$2.94M$3.93M$4.88M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$6.95M$3.59M$8.24M$19.7M$33M
Property, plant and equipment, net$290K$420K$320K$410K$30K
Goodwill and intangible assets$1M$5.33M$7.23M$4.5M$2.71M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$2.58M$5.76M$7.58M$4.94M$2.77M
Total assets$9.53M$9.35M$15.8M$24.6M$35.7M
Accounts payable$5.36M$4.2M$3.93M$2.46M$830K
Short-term debt$60K$40K$170K$160K$0.00
Deferred revenue$190K$360K$420K$0.00$650K
Total current liabilities$6.23M$5.77M$6.05M$4.28M$2.51M
Long-term debt$210K$270K$30K$30K$3.42M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$210K$270K$30K$30K$3.42M
Capital lease obligations$270K$310K$200K$190K$0.00
Total liabilities$6.44M$6.04M$6.08M$4.31M$5.93M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-82.35M-$-71.86M-$-59.36M-$-48.27M-$-38.02M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$3.09M$3.31M$9.74M$20.3M$29.8M
Total investments$0.00$0.00$2.66M$0.00$0.00
Total debt$270K$310K$200K$190K$3.42M
Net debt-$-6.61M-$-1.57M-$-2.15M-$-15.12M-$-24.32M
Cash flow statement
20252024202320222021
Net income-$-10.49M-$-12.5M-$-11.1M-$-10.25M-$-8.96M
Depreciation and amortization$1.66M$2.29M$2.12M$1.21M$1M
Stock-based compensation$20K$250K$460K$680K$620K
Change in working capital$2.11M-$-500K$2.59M$2.35M-$-5.28M
Accounts receivable$1.34M-$-400K$820K$710K-$-2.68M
Inventory$50K$0.00$0.00$0.00$0.00
Accounts payable$1.24M$270K$1.47M$1.63M-$-960K
Net cash provided by operating activities-$-4.24M-$-8.26M-$-5.81M-$-5.82M-$-10.67M
Investments in property, plant and equipment-$0.00-$-30K-$-20K-$-220K-$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-1M$1.98M-$-7.23M-$-3.19M-$-1.04M
Common stock issued$10.2M$1.89M$0.00$0.00$41.5M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$10.2M$5.82M$70K-$-3.42M$38.8M
Net change in cash$5M-$-470K-$-12.97M-$-12.43M$27M
Cash at end of period$6.88M$1.88M$2.34M$15.3M$27.7M
Operating cash flow-$-4.24M-$-8.26M-$-5.81M-$-5.82M-$-10.67M
Capital expenditure-$0.00-$-60K-$-4.74M-$-3.19M-$-1.04M
Free cash flow-$-4.24M-$-8.3M-$-10.55M-$-9.01M-$-11.71M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About iSpecimen Inc.

        iSpecimen Inc. operates a sophisticated technological platform that effectively bridges the gap between life science researchers and crucial human biological materials. Its proprietary cloud-based system empowers scientists to efficiently locate and access a vast array of biospecimens—such as biofluids, tissues, and living cells—as well as connect with potential study subjects, all sourced from a global network of healthcare providers, including hospitals, laboratories, biobanks, and blood centers. The company develops and manages iSpecimen Marketplace, an innovative online hub that strategically links medical researchers requiring access to subjects, samples, and pertinent data with organizations that hold these invaluable resources. iSpecimen's clientele primarily includes biopharmaceutical firms, in vitro diagnostics companies, and governmental and academic research institutions. The company, established in 2009, is headquartered in Lexington, Massachusetts.

        CEO
        Katharyn Field
        Employees
        7
        Beta
        1.63

        Explore

        Frequently asked questions

        What is the intrinsic value of iSpecimen Inc. (ISPC)?

        InvestorsCraft does not currently publish an intrinsic value for ISPC. How the IC value is calculated.

        Is ISPC undervalued?

        InvestorsCraft does not publish an undervaluation signal for ISPC at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.